Canon Medical System Corporation partners with ACT Genomics for Precision Cancer Medicine Service in Japan
TAIPEI, Taiwan, Sept. 21, 2018 /PRNewswire/ -- Canon Medical System Corporation (Canon Medical) completed the acquisition of the majority shares of ACTmed - a joint venture company established with ACT Genomics (ACTG), a Taiwanese molecular diagnostic company. ACTG will transfer its clinical NGS technology to ACTmed, making ACTG the first Taiwanese biotech company to transfer technology to a major medical company in Japan. ACTG will also help ACTmed to operate cancer genomic profiling service in Japan and be the provider for analyzing the sequencing data generated by ACTmed.
Through this partnership, ACTG and Canon Medical will utilize caner genomic testing to provide cancer treatment selection and disease monitoring with better precision to patients in Japan.
Founded in 2014, ACTG is the Asia leading DNA cancer solution providers and transforms science into actionable solutions empowering clinicians and patients with evidence-based information to fight cancer. The Company's mission is to provide every cancer patient with personalized genomic information-based treatment plans through the cutting-edge Next Generation Sequencing ("NGS") platform, Asian genome database, leading professional bioinformatics and biomedical team in Asia, medical report, and integrated services.
ACTG's flagship NGS panel, ACTOnco, investigates 440 cancer-related genes by incorporating a signaling pathway design. ACTOnco provides optimal treatment suggestion to clinicians, including targeted therapies, hormonal therapies, chemotherapies, and immunotherapies, for all solid tumor types.
Currently, ACTG operates in Taiwan, Hong Kong, Singapore and Japan.
Founded in 2014, ACTG provides optimal cancer treatment plan, cancer relapse and drug resistance monitoring as well as cancer risk assessment and immunotherapy evaluation. The company achieves precise cancer genetic variants detection with minimum tumor samples, and delivers to every cancer patient personalized genomic information based-treatment plans through cutting-edge NGS platform, medical report and integrated services. The company also provides comprehensive data analysis on cancer genomics applying Artificial Intelligence and integrates genomic databases information with Asia specific genome profiling.
ACTG's comprehensive portfolio received the 2017 Asia Pacific Molecular Diagnostics Product Line Strategy Leadership Award by Frost & Sullivan.
SOURCE ACT Genomics